Hua Medicine (Shanghai) Ltd.

SEHK:2552 Stock Report

Market Cap: HK$1.5b

Hua Medicine (Shanghai) Past Earnings Performance

Past criteria checks 0/6

Hua Medicine (Shanghai) has been growing earnings at an average annual rate of 43.5%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 53.6% per year.

Key information

43.5%

Earnings growth rate

48.4%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate53.6%
Return on equityn/a
Net Margin-241.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Nov 17
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

Aug 28
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

Jan 06
We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Aug 02
We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Apr 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Sep 23
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Jun 24
We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Mar 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Feb 21
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Jan 25
Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Dec 21
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Revenue & Expenses Breakdown

How Hua Medicine (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2552 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24109-263219220
31 Mar 2493-237212196
31 Dec 2377-211204172
30 Sep 2382-200194150
30 Jun 2388-189184128
31 Mar 2353-196164129
31 Dec 2218-204145130
30 Sep 229-234143145
30 Jun 220-265140161
31 Mar 220-295137174
31 Dec 210-326135187
30 Sep 214-355137197
30 Jun 219-385139207
31 Mar 219-389140214
31 Dec 209-393140221
30 Sep 2016-378138244
30 Jun 2023-363137268
31 Mar 2022-394142295
31 Dec 1922-425147322
30 Sep 1912-1,379144331
30 Jun 193-2,333142340
31 Mar 193-3,399124309
31 Dec 189-3,603100269
30 Sep 1813-2,57876228
30 Jun 1817-1,55452186
31 Mar 1816-44041158
31 Dec 1711-27331125
31 Dec 161-3611975

Quality Earnings: 2552 is currently unprofitable.

Growing Profit Margin: 2552 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2552 is unprofitable, but has reduced losses over the past 5 years at a rate of 43.5% per year.

Accelerating Growth: Unable to compare 2552's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2552 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).


Return on Equity

High ROE: 2552's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 11:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hua Medicine (Shanghai) Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCLSA
Bo LiCLSA
Ziyi ChenGoldman Sachs